MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze GKOS →
    • FindStock Picks / Stock Screener
    • Value · GKOSIntrinsic Value Calculator
    • Invest · GKOSInvestment Case
    • Hold · GKOS5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
GKOS stock logo

GKOS

Glaukos Corporation

$233.04
-5.57
 (-2.33%)
Exchange:  NYSE
Market Cap:  13.795B
Shares Outstanding:  57.19M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Medical – DevicesView industry performance
   
CEO:  Thomas William Burns
Full Time Employees:  1094
Address: 
One Glaukos Way
Aliso Viejo
CA
92656
US
Website:  https://www.glaukos.com
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos’s micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
GKGKOS logoGKOSGlaukos Corporation13.8B—388-7.2%
SNSNN logoSNNSmith & Nephew plc12.6B19.513.88.8%
PEPEN logoPENPenumbra, Inc.12.6B79.968.77.9%
ALALGN logoALGNAlign Technology, Inc.10.8B21.813.610.4%
POPODD logoPODDInsulet Corp.10.7B27.923.816.0%
GMGMED logoGMEDGlobus Medical, Inc.10.7B19.715.910.5%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/04/29 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue314,711383,481507,442
Gross Profit239,136289,454393,216
EBITDA-82,116-95,639-146,062
Operating Income-128,700-122,366-86,733
Net Income-134,661-146,372-187,691

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets940,414974,756893,487
Total Liabilities478,648207,825237,332
Total Stockholders Equity461,766766,931656,155
Total Debt383,738103,399139,643
Cash and Cash Equivalents93,467169,62690,813

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-57,758-61,318-46,340
Capital Expenditure-20,248-6,300-7,666
Free Cash Flow-78,006-67,618-54,006
Net Income-134,661-146,372-133,657
Net Change in Cash-27,28075,036-111,263

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)1,720,897.652Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,895,870.618Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)1,818,250Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)453,084.197Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)501,535.711Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)480,041.682Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)284,670.092Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)322,946.788Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)305,966.505Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,148,923.848Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,265,741.145Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,213,919.249Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)5.350Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)5.650Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)4.980Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)6Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
383.481M  ?P/S
 (TTM)
: 
20.37
?Net Income
 (TTM)
: 
-146.372M  ?P/E
 (TTM)
: 
-80.82
?Enterprise Value
 (TTM)
: 
14.005B  ?EV/FCF
 (TTM)
: 
388.81
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-24.91%  ?ROIC
 (TTM)
: 
-7.22%
?Net Debt
 (TTM)
: 
-213.042M  ?Debt/Equity
 (TTM)
: 
0.14
?P/B
 (TTM)
: 
19.58  ?Current Ratio
 (TTM)
: 
4.57

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
388.40Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates GKOS intrinsic value between $49.66 – $74.20 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate GKOS Intrinsic Value

Common questions about GKOS valuation

Is Glaukos Corporation (GKOS) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Glaukos Corporation (GKOS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is GKOS a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GKOS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is GKOS’s P/E ratio?

You can see GKOS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for GKOS?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is GKOS a good long-term investment?

Whether GKOS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Glaukos Corporation

  • Glaukos Corporation intrinsic value calculatorEstimate what the business is worth
  • Glaukos Corporation 5-year outlookWhat has to go right, and what could go wrong
GKOS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-2.33
MarketSnap

Trading Metrics:

Open: 239.32   Previous Close: 238.61
Day Low: 230.36   Day High: 240.94
Year Low: 80.91   Year High: 248.75
Price Avg 50: 175.31   Price Avg 200: 142.64
Volume: 10.707M   Average Volume: 947473

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
29-10-2026 04:55
Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript
28-10-2026 22:20
Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript
State of Alaska Department of Revenue Sells 9,393 Shares of Glaukos Corporation $GKOS
20-10-2026 03:53
State of Alaska Department of Revenue Sells 9,393 Shares of Glaukos Corporation $GKOS
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
14-10-2026 14:41
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
09-10-2026 13:17
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
09-10-2026 12:49
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze GKOS →
    • FindStock Picks / Stock Screener
    • Value · GKOSIntrinsic Value Calculator
    • Invest · GKOSInvestment Case
    • Hold · GKOS5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read